Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2017 3 572 M
EBIT 2017 1 126 M
Net income 2017 920 M
Debt 2017 1 687 M
Yield 2017 0,45%
Sales 2018 4 452 M
EBIT 2018 1 418 M
Net income 2018 1 188 M
Debt 2018 1 112 M
Yield 2018 0,52%
P/E ratio 2017 24,84
P/E ratio 2018 19,27
EV / Sales2017 6,86x
EV / Sales2018 5,37x
Capitalization 22 812 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
02/24 3SBIO : says 3 products listed in 2017 National Drug List
2016 3SBIO : granted exclusive license of diabetes drugs
2016 3SBIO : AstraZeneca Ink Licensing Agreement
2016 3SBIO : gets nod for colorectal cancer drug clinical trial
2016 3SBIO INC. : (01530) says ITP drug get clinical trial approval
2016 3SBIO INC. : (01530) withdraws breast cancer drug application
2016DJChinese Drugmaker Plans up to $3 Billion Hong Kong IPO
2015 3SBIO : Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap I..
2015 3SBIO : Acquires Zhejiang Wansheng Pharmaceutical
2015 3SBIO : Acquires Global Rights to Anti-TNF mAb
More news
Sector news : Biopharmaceuticals
03:01a Becton Dickinson to acquire Bard for $24 billion
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
More sector news : Biopharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 10,3  CNY
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer, President-R&D
Dong Mei Su Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)0.00%3 314
BIOGEN INC4.44%58 942
CSL LIMITED27.90%43 947
ALEXION PHARMACEUTICAL..-4.52%26 302
GRIFOLS SA25.00%16 002
BIOMARIN PHARMACEUTICA..6.80%15 293
More Results